Cargando…

Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring

AIMS/INTRODUCTION: To assess the effects of sodium glucose co-transporter 2 inhibitor therapy on the pathophysiology of type 2 diabetes. MATERIALS AND METHODS: We administered ipragliflozin to 21 inpatients with type 2 diabetes for 7 days, and analyzed the diurnal profiles of plasma glucose and 3-hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Kentaro, Nakayama, Hitomi, Yoshinobu, Satoko, Kawano, Seiko, Tsuruta, Munehisa, Nohara, Masayuki, Hasuo, Rika, Akasu, Shoko, Tokubuchi, Ichiro, Wada, Nobuhiko, Hirao, Saori, Iwata, Shinpei, Kaku, Hiroo, Tajiri, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627548/
https://www.ncbi.nlm.nih.gov/pubmed/26543545
http://dx.doi.org/10.1111/jdi.12370
_version_ 1782398297467518976
author Yamada, Kentaro
Nakayama, Hitomi
Yoshinobu, Satoko
Kawano, Seiko
Tsuruta, Munehisa
Nohara, Masayuki
Hasuo, Rika
Akasu, Shoko
Tokubuchi, Ichiro
Wada, Nobuhiko
Hirao, Saori
Iwata, Shinpei
Kaku, Hiroo
Tajiri, Yuji
author_facet Yamada, Kentaro
Nakayama, Hitomi
Yoshinobu, Satoko
Kawano, Seiko
Tsuruta, Munehisa
Nohara, Masayuki
Hasuo, Rika
Akasu, Shoko
Tokubuchi, Ichiro
Wada, Nobuhiko
Hirao, Saori
Iwata, Shinpei
Kaku, Hiroo
Tajiri, Yuji
author_sort Yamada, Kentaro
collection PubMed
description AIMS/INTRODUCTION: To assess the effects of sodium glucose co-transporter 2 inhibitor therapy on the pathophysiology of type 2 diabetes. MATERIALS AND METHODS: We administered ipragliflozin to 21 inpatients with type 2 diabetes for 7 days, and analyzed the diurnal profiles of plasma glucose and 3-hydroxybutyrate. A total of 21 age-, sex- and body mass index-matched diabetic patients served as controls. RESULTS: Continuous glucose monitoring showed that the 24-h glucose curve was shifted downward without hypoglycemia by the administration of ipragliflozin. The average glucose level was reduced from 182 ± 54 mg/dL to 141 ± 33 mg/dL (P < 0.0001). The magnitude of the reduction was highly correlated with the baseline average glucose level. Homeostasis model assessment of insulin resistance was decreased, and homeostasis model assessment of β-cell function was increased during the treatment. Urinary glucose excretion was correlated with the average glucose level both on day 0 and on day 7, although the regression line was steeper and shifted leftward on day 7. The ipragliflozin-treated patients lost more weight than the control patients (1.4 ± 0.5 vs 0.5 ± 0.6 kg, P < 0.0001). Plasma levels of 3-hydroxybutyrate were significantly increased with peaks before breakfast and before dinner. Patient age and bodyweight loss were negatively and positively correlated with the peak levels of 3-hydroxybutyrate on day 7, respectively. CONCLUSIONS: The ipragliflozin treatment improved the 24-h glucose curve without causing hypoglycemia. The close correlation between the magnitude of glucose reduction and the baseline plasma glucose concentration suggests that the risk of hypoglycemia is likely low. It might be prudent to monitor ketone body levels in younger patients and in patients with rapid weight loss.
format Online
Article
Text
id pubmed-4627548
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-46275482015-11-05 Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring Yamada, Kentaro Nakayama, Hitomi Yoshinobu, Satoko Kawano, Seiko Tsuruta, Munehisa Nohara, Masayuki Hasuo, Rika Akasu, Shoko Tokubuchi, Ichiro Wada, Nobuhiko Hirao, Saori Iwata, Shinpei Kaku, Hiroo Tajiri, Yuji J Diabetes Investig Articles AIMS/INTRODUCTION: To assess the effects of sodium glucose co-transporter 2 inhibitor therapy on the pathophysiology of type 2 diabetes. MATERIALS AND METHODS: We administered ipragliflozin to 21 inpatients with type 2 diabetes for 7 days, and analyzed the diurnal profiles of plasma glucose and 3-hydroxybutyrate. A total of 21 age-, sex- and body mass index-matched diabetic patients served as controls. RESULTS: Continuous glucose monitoring showed that the 24-h glucose curve was shifted downward without hypoglycemia by the administration of ipragliflozin. The average glucose level was reduced from 182 ± 54 mg/dL to 141 ± 33 mg/dL (P < 0.0001). The magnitude of the reduction was highly correlated with the baseline average glucose level. Homeostasis model assessment of insulin resistance was decreased, and homeostasis model assessment of β-cell function was increased during the treatment. Urinary glucose excretion was correlated with the average glucose level both on day 0 and on day 7, although the regression line was steeper and shifted leftward on day 7. The ipragliflozin-treated patients lost more weight than the control patients (1.4 ± 0.5 vs 0.5 ± 0.6 kg, P < 0.0001). Plasma levels of 3-hydroxybutyrate were significantly increased with peaks before breakfast and before dinner. Patient age and bodyweight loss were negatively and positively correlated with the peak levels of 3-hydroxybutyrate on day 7, respectively. CONCLUSIONS: The ipragliflozin treatment improved the 24-h glucose curve without causing hypoglycemia. The close correlation between the magnitude of glucose reduction and the baseline plasma glucose concentration suggests that the risk of hypoglycemia is likely low. It might be prudent to monitor ketone body levels in younger patients and in patients with rapid weight loss. John Wiley & Sons, Ltd 2015-11 2015-06-20 /pmc/articles/PMC4627548/ /pubmed/26543545 http://dx.doi.org/10.1111/jdi.12370 Text en © 2015 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Yamada, Kentaro
Nakayama, Hitomi
Yoshinobu, Satoko
Kawano, Seiko
Tsuruta, Munehisa
Nohara, Masayuki
Hasuo, Rika
Akasu, Shoko
Tokubuchi, Ichiro
Wada, Nobuhiko
Hirao, Saori
Iwata, Shinpei
Kaku, Hiroo
Tajiri, Yuji
Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
title Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
title_full Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
title_fullStr Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
title_full_unstemmed Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
title_short Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
title_sort effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: a study using continuous glucose monitoring
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627548/
https://www.ncbi.nlm.nih.gov/pubmed/26543545
http://dx.doi.org/10.1111/jdi.12370
work_keys_str_mv AT yamadakentaro effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT nakayamahitomi effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT yoshinobusatoko effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT kawanoseiko effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT tsurutamunehisa effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT noharamasayuki effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT hasuorika effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT akasushoko effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT tokubuchiichiro effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT wadanobuhiko effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT hiraosaori effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT iwatashinpei effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT kakuhiroo effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring
AT tajiriyuji effectsofasodiumglucosecotransporter2selectiveinhibitoripragliflozinonthediurnalprofileofplasmaglucoseinpatientswithtype2diabetesastudyusingcontinuousglucosemonitoring